As seen in Chain Drug Review’s Diabetes Care Report.
Approximately 15% of people with diabetes suffer from foot ulcers, and treating them properly can be challenging for the patient. However, failure to do so, with resulting infection, carries the danger of eventual amputation.
By Marc A. Brenner, DPM | Podiatry Management, Clinical Innovations, The Diabetic Foot.
Wound pain has numerous, often interlinked, causes that may relate to the initial injury, the inflammatory response or infection. Pain may also result from interventions, such as dressing removal, cleansing, debridement, compression therapy, or topical treatments. Pain as a result of trauma, particularly during the dressing change procedure, has been described by patients as the worst part of dealing with a wound.1
MDose™ Technology Background It has been shown that convenience, ease of dispensing and favorable tolerability are key characteristics that may increase patient compliance with topical dermatologic therapy.,, Additionally, the quantity of drug utilized with...
Gensco Pharma Announces Additions to 2017 CGDP on CMS Gensco products will be available to MEDICARE patients in 2017
Gensco Pharma is a FDA licensed pharmaceutical manufacturer focusing on the research, development and marketing of transdermal prescription products. As an innovator of pharmaceutical products, Gensco Pharma currently delivers non-narcotic transdermal analgesic gels...
By Gary E. Myerson, MD, Marc Alan Brenner, DPM, Robert L. Wilbur, Pharm.D., CPh | Director, Medical Affairs
A new agent, ColciGel®, has recently emerged for the treatment of acute flares of gout. ColciGel is a transdermal gel preparation of Colchicinum (colchicine in its homeopathic state) that is applied topically. ColciGel contains Colchicinum 4X in a proprietary Organogel that is applied directly to the site of acute flares.
Transdermal Pharmaceuticals Clinically Proven APPA | September 2016 Chain Drug Review | July 2016 Chain Drugstore Daily | April 2016
By Gary E. Myerson, MD
Oral Colchicine was effective in only 38% of patients treated for acute flares.1 It is associated with poor tolerability due to a high-rate of gastrointestinal effects; typically nausea, vomiting, abdominal cramps and diarrhea. Less common but more significant is a strong potential for drug-drug interactions with oral colchicine as it is metabolized and transported by cytochrome P450-3A4 and P-glycoprotein, two systems used by many other drugs.2 Fatalities have occurred from these drug-drug interactions with colchicine.3 4
Astero™ is a FDA approved hydrogel plus topical anesthetic (Lidocaine 4%) indicated for painful wounds such as post-surgical incisions, ulcers, cuts and abrasions. Chain Drug Review | November 2016 Chain Drug Review | September 2016 Podiatry Management | August 2016...
By Alesia Wagner, Chain Drug Review
Gout, an extremely painful form of inflammatory arthritis, affects more than 4% of Americans and about 10% of men over the age of 60. It is more common in women after menopause. The disease occurs due to an excess of the bodily waste uric acid. The acid is deposited as needle-like crystals in the joints or in soft tissue. These crystals cause redness, swelling, stiffness and intense pain in the joints, which in turn can create gout flares.
ColciGel is a new prescription medication for the treatment of acute flares of gout. It is a transdermal gel that contains homeopathic colchicine (colchicinum 4X) that is applied directly to the sites of a flare. ColciGel penetrates the dermal layer, resulting in the reduction of inflammation and pain associated with the flare.